Home › Research › Lewy body dementia
Phenome-wide and proteomic analysis of APOE alleles across different ancestries in the All of Us Research Program
Mejia-Garcia A, Valderrama-Carmona P, Zheng TM, Wang Z, Tsao HM, Jung J, Orozco CA, Su C et al.. medRxiv, 2026-09-28
Topic: Genetics and APOE
Plain-language summary
Findings We identified 27 phenotypes associated with APOE, mainly in neurological and lipid-related traits. Finally, SNAP25 was identified as positively associated with APOE ε4 dosage across ancestries, and CDC42EP1, APOA1 and ITGB5 shown associations with APOE ε2/ε4 specifically in non-European populations. A recent APOE PheWAS in the All of Us Research Program (n = 181,880) identified 17 Bonferroni-significant phenotypes and preliminary evidence of ancestry heterogeneity for hyperlipidemia and mild cognitive impairment, but statistical power in non-European groups limited systematic characterization of ancestry-specific effects. We identify 27 Bonferroni-significant phecodes, 11 novel compared to the previous APOE PheWAS in All of Us — including vascular dementia, dementia with Lewy bodies, and angina pectoris. We detect significant sex heterogeneity for five lipid-related phecodes and significant ancestry heterogeneity for nine phecodes, including stronger protection against fatty liver and chronic liver disease in East Asian participants and larger dementia risk in European participants. Implications of all the available evidence APOE-associated risk estimates derived predominantly from European-ancestry data may not transfer directly to other populations, and our findings support incorporating ancestry into the interpretation and calibration of APOE-based risk prediction.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mejia-Garcia, A., Valderrama-Carmona, P., Zheng, T. M., Wang, Z., Tsao, H. M., Jung, J., et al. (2026). Phenome-wide and proteomic analysis of APOE alleles across different ancestries in the All of Us Research Program. medRxiv. https://doi.org/10.64898/2026.09.26.26364080
Vancouver
Mejia-Garcia A, Valderrama-Carmona P, Zheng TM, Wang Z, Tsao HM, Jung J, et al. Phenome-wide and proteomic analysis of APOE alleles across different ancestries in the All of Us Research Program. medRxiv. 2026. doi:10.64898/2026.09.26.26364080.
BibTeX
@article{mejiagarcia2026-600a905d,
author = {Mejia-Garcia, A. and Valderrama-Carmona, P. and Zheng, T. M. and Wang, Z. and Tsao, H. M. and Jung, J. and Orozco, C. A. and Su, C. and others},
title = {{Phenome-wide and proteomic analysis of APOE alleles across different ancestries in the All of Us Research Program}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.09.26.26364080},
url = {https://doi.org/10.64898/2026.09.26.26364080}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Findings We identified 27 phenotypes associated with APOE, mainly in neurological and lipid-related traits.
- Finally, SNAP25 was identified as positively associated with APOE ε4 dosage across ancestries, and CDC42EP1, APOA1 and ITGB5 shown associations with APOE ε2/ε4 specifically in non-European populations.
- A recent APOE PheWAS in the All of Us Research Program (n = 181,880) identified 17 Bonferroni-significant phenotypes and preliminary evidence of ancestry heterogeneity for hyperlipidemia and mild cognitive impairment, but statistical power in non-European groups limited systematic characterization of ancestry-specific effects.
- We identify 27 Bonferroni-significant phecodes, 11 novel compared to the previous APOE PheWAS in All of Us — including vascular dementia, dementia with Lewy bodies, and angina pectoris.
- We detect significant sex heterogeneity for five lipid-related phecodes and significant ancestry heterogeneity for nine phecodes, including stronger protection against fatty liver and chronic liver disease in East Asian participants and larger dementia risk in European participants.
Study details
- Participants181,880
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 35 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 22 of the 62 points we could judge it on, which is 35 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 181,880 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 22 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 22 of the 62 points we could judge it on is 35 out of 100. |
| Total | 35 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Lewy body dementia from nearby years
Also tagged “apoe2”
265 studies in the library carry the topic tag “apoe2”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 265 tagged studies.